Display Settings:

Format

Send to:

Choose Destination
    Eur Neuropsychopharmacol. 1994 Dec;4(4):479-86.

    A trial of carbamazepine in borderline personality disorder.

    Source

    Department of Psychiatry, Erasme Hospital, Free University of Brussels (ULB), Belgium.

    Abstract

    Borderline personality disorder does not have a first choice pharmacological treatment. We studied 20 borderline inpatients in a double-blind parallel placebo-controlled trial with carbamazepine for a mean of 30.9 days. No significant positive effects of the drug were found.

    PMID:
    7894258
    [PubMed - indexed for MEDLINE]

    LinkOut - more resources

    Full Text Sources

    Molecular Biology Databases

      Supplemental Content

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk